Local Treatment of Remaining Tumors Versus Continued Immunotherapy in Metastatic Non-Small Cell Lung Cancer
Compares treating leftover tumors locally with continuing drug therapy in metastatic lung cancer.
Plain-language title generated from the registry record
Registry title: Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IV non-small cell lung cancer whose tumours shrank after first-line immunotherapy plus chemotherapy, and who still have a few active leftover lesions that local treatment can reach.
- Age
- 18 years or older
- Sex
- Both men and women can join.
- Disease stage
- Stage IV non-small cell lung cancer (IASLC 9th edition), with no actionable gene changes such as EGFR/ALK/ROS1. Partial or complete response to first-line treatment. Leftover active lesions on PET that a specialist team judges treatable locally (for example, no more than 3 organs and no more than 5 lesions).
- Earlier treatment
- Must have finished 4-6 cycles of PD-1/PD-L1 immunotherapy together with platinum-based double chemotherapy before joining.
- Biomarker or test result
- No actionable gene changes (EGFR/ALK/ROS1 and other druggable targets).
Main reasons for not taking part
- Cannot have local treatment (surgery, radiotherapy or ablation) for all active leftover lesions
- History of malignant pleural effusion or pleural spread
- Neuroendocrine lung cancer at first diagnosis, including small cell lung cancer
- Previous solid organ or other allogeneic tissue transplant
- Positive HIV test, or active hepatitis B or hepatitis C
Read by machine on 12 November 2026.
Where in China
- Guangdong Provincial People's HospitalGuangzhou, ChinaContact: Wen-Zhao Zhong, MD,PhDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Guangdong Provincial People's Hospital
- Trial code
- NCT07842471
- Record updated
- 25 September 2026
- Original description
This study explores the difference in progression-free survival (PFS) between local consolidative therapy (LCT arm) targeting residual lesions and continued systemic therapy (non-LCT arm) in patients with metastatic NSCLC who have achieved at least partial response (PR) following first-line chemoimmunotherapy. In this process, a multidisciplinary team (MDT) comprising surgical oncology, radiation oncology, and medical oncology will be integrated to administer local treatment modalities-including surgery, radiotherapy, and ablation-for oligometastatic lesions, aiming to address critical clinical questions regarding the optimal beneficiary population for local therapy, the best local treatment modality, and the optimal timing of local intervention.Read full original descriptionShow less
A Phase II, Multicenter, Randomized, Patient-Centered Study of the Efficacy and Safety of Immediate Local Consolidative Therapy (LCT) Versus Continued Immunotherapy Maintenance or Delayed Local Therapy (Non-LCT) After First-Line Chemoimmunotherapy in Metastatic NSCLC, Assessed by MDT
This study explores the difference in progression-free survival (PFS) between local consolidative therapy (LCT arm) targeting residual lesions and continued systemic therapy (non-LCT arm) in patients with metastatic NSCLC who have achieved at least partial response (PR) following first-line chemoimmunotherapy. In this process, a multidisciplinary team (MDT) comprising surgical oncology, radiation oncology, and medical oncology will be integrated to administer local treatment modalities-including surgery, radiotherapy, and ablation-for oligometastatic lesions, aiming to address critical clinical questions regarding the optimal beneficiary population for local therapy, the best local treatment modality, and the optimal timing of local intervention.
Inclusion: Voluntary participation in the study with signed informed consent; Age ≥18 years, both male and female; Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; Estimated life expectancy ≥12 months; Histologically/cytologically confirmed non-small cell lung cancer (NSCLC) at initial diagnosis, with TNM stage IV (IASLC 9th edition); Absence of actionable genetic mutations related to EGFR/ALK/ROS1 and other druggable targets; Completion of 4-6 cycles of immunotherapy (PD-1/PD-L1 monoclonal antibody) combined with platinum-based doublet chemotherapy prior to enrollment; Achievement of partial response (PR) or complete response (CR) as assessed by RECIST 1.1 criteria; Presence of metabolically active residual lesions on PET evaluation, and clinical assessment by the multidisciplinary team (MDT)* indicating feasibility of individualized local therapy (e.g., ≤3 organs and ≤5 lesions, amenable to surgery/radiotherapy/ablation); Adequate organ function.
Exclusion: Expected to be unable to tolerate surgery, radiation therapy, or ablation; Previously received allogeneic tissue or solid organ transplantation; Participants with uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg (adjustment of antihypertensive medications is allowed prior to study initiation, but the average of the most recent three consecutive blood pressure readings before enrollment must be ≤150/90 mmHg) (each measurement separated by at least 2 minutes); Diagnosis of another malignancy within 3 years prior to signing informed consent, excluding cured cases of cutaneous basal cell carcinoma, cervical or breast in situ carcinoma, superficial bladder cancer, localized prostate cancer; participants with low-risk early-stage prostate cancer (T1-T2a stage, Gleason score ≤6, PSA <10 ng/mL) are eligible if they have undergone curative treatment or are under active surveillance with stable disease, regardless of whether they have received treatment; Pregnant, breastfeeding, or planning pregnancy; positive pregnancy test within 7 days prior to first study treatment; Patients with a confirmed history of malignant pleural effusion or pleural dissemination; Pathologically diagnosed with neuroendocrine cancer at initial diagnosis (including small cell lung cancer, combined small cell lung cancer, large cell neuroendocrine carcinoma, mixed large cell neuroendocrine carcinoma, and carcinoid). Patients who do not show neuroendocrine components at initial diagnosis but develop such components in post-surgical pathology may be included; History of interstitial lung disease requiring steroid treatment (non-infectious) or currently suffering from interstitial lung disease requiring steroid treatment; Active infection requiring intravenous antimicrobial therapy at screening; Conditions that may interfere with interpretation of study results or affect the participant's ability to complete the entire study, or where, in the investigator's judgment, participation does not serve the participant's best interest; Presence of viral infectious diseases during screening:; Positive serum test for human immunodeficiency virus (HIV); Active hepatitis B: positive hepatitis B surface antigen (HBsAg) and HBV-DNA quantitative test >500 IU/mL or >2000 copies/mL; Active hepatitis C: positive hepatitis C virus (HCV) antibody and HCV-RNA quantitative test above the upper limit of normal; Unable to receive local treatment for all active residual lesions; Poor compliance, unwillingness or inability to follow the study procedures as required.